Shares of Allena Pharmaceuticals Inc (NASDAQ:ALNA) have received an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus target price of $26.00 for the company, according to Zacks. Zacks has also given Allena Pharmaceuticals an industry rank of 101 out of 265 based on the ratings given to related companies.

ALNA has been the subject of several recent research reports. Credit Suisse Group initiated coverage on Allena Pharmaceuticals in a report on Monday, November 27th. They set an “outperform” rating and a $22.00 price target for the company. Jefferies Group initiated coverage on Allena Pharmaceuticals in a report on Monday, November 27th. They set a “buy” rating and a $22.00 price target for the company. Cowen started coverage on Allena Pharmaceuticals in a report on Monday, November 27th. They set an “outperform” rating for the company. Finally, Wedbush started coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating and a $30.00 price objective for the company.

In other news, major shareholder Bessemer Venture Partners Vii bought 36,000 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $504,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director James N. Topper bought 500,000 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $7,000,000.00. The disclosure for this purchase can be found here.

Shares of Allena Pharmaceuticals (NASDAQ ALNA) opened at $12.38 on Friday. Allena Pharmaceuticals has a fifty-two week low of $8.66 and a fifty-two week high of $15.40.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/brokerages-set-26-00-target-price-for-allena-pharmaceuticals-inc-alna/1765017.html.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Get a free copy of the Zacks research report on Allena Pharmaceuticals (ALNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.